These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575 [TBL] [Abstract][Full Text] [Related]
12. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines. Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053 [TBL] [Abstract][Full Text] [Related]
13. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin. Zhu H; Yun F; Shi X; Wang D Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422 [TBL] [Abstract][Full Text] [Related]
14. ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells. Durinikova E; Kozovska Z; Poturnajova M; Plava J; Cierna Z; Babelova A; Bohovic R; Schmidtova S; Tomas M; Kucerova L; Matuskova M BMC Cancer; 2018 Aug; 18(1):848. PubMed ID: 30143021 [TBL] [Abstract][Full Text] [Related]
15. Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours. Roška J; Lobo J; Ivovič D; Wachsmannová L; Mueller T; Henrique R; Jerónimo C; Chovanec M; Jurkovičová D Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768818 [TBL] [Abstract][Full Text] [Related]
16. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464 [TBL] [Abstract][Full Text] [Related]
17. Novel sequential therapy with metformin enhances the effects of cisplatin in testicular germ cell tumours via YAP1 signalling. He K; Li Z; Ye K; Zhou Y; Yan M; Qi H; Hu H; Dai Y; Tang Y Cancer Cell Int; 2022 Mar; 22(1):113. PubMed ID: 35264157 [TBL] [Abstract][Full Text] [Related]
18. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition. Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial. Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178 [TBL] [Abstract][Full Text] [Related]
20. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]